SCF βTrCP mediates stress-activated MAPK-induced Cdc25B degradation

Journal of Cell Science

Volumn 124, Issue 16, 2011, Pages 2816-2825

  Uchida, Sanae ^a   Watanabe, Nobumoto ^b   Kudo, Yasusei ^c   Yoshioka, Katsuji ^a   Matsunaga, Tsukasa ^a   Ishizaka, Yukihito ^d   Nakagama, Hitoshi ^e   Poon, Randy Y C ^f   Yamashita, Katsumi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b RIKEN   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^f HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Cdc25B; PEST like; Phosphorylation; SCF TrCP

Indexed keywords

ALANINE; CDC25B PROTEIN PHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN PHOSPHATASE; SERINE; SKP1 CULLIN 1 F BOX PROTEIN E3 UBIQUITIN LIGASE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CELL STRAIN COS7; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; UBIQUITINATION;

ANIMALS; CDC25 PHOSPHATASES; DNA DAMAGE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MICE; MUTAGENESIS, SITE-DIRECTED; MUTATION; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 12; PROTEOLYSIS; SERINE; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITINATION;

MAMMALIA;

EID: 79961138970     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.083931     Document Type: Article

References (35)

1. Baldin, V., Cans, C., Superti-Furga, G. and Ducommun, B. (1997). Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control? Oncogene 14, 2485-2495.
2. Bartek, J., Lukas, C. and Lukas, J. (2004). Checking on DNA damage in S phase. Nat. Rev. Mol. Cell Biol. 5, 792-804.
3. Boutros, R., Dozier, C. and Ducommun, B. (2006). The when and wheres of CDC25 phosphatases. Curr. Opin. Cell Biol. 18, 185-191.
4. Boutros, R., Lobjois, V. and Ducommun, B. (2007). CDC25 phosphatases in cancer cells: key players? Good targets? Nat. Rev. Cancer 7, 495-507.
5. Busino, L., Donzelli, M., Chiesa, M., Guardavaccaro, D., Ganoth, D., Dorrello, N. V., Hershko, A., Pagano, M. and Draetta, G. F. (2003). Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426, 87-91.
6. Busino, L., Chiesa, M., Draetta, G. F. and Donzelli, M. (2004). Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 23, 2050-2056.
7. Chen, M. S., Hurov, J., White, L. S., Woodford-Thomas, T. and Piwnica-Worms, H. (2001). Absence of apparent phenotype in mice lacking Cdc25C protein phosphatase. Mol. Cell. Biol. 21, 3853-3861.
8. Donzelli, M. and Draetta, G. F. (2003). Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep. 4, 671-677.
9. Ferguson, A. M., White, L. S., Donovan, P. J. and Piwnica-Worms, H. (2005). Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases. Mol. Cell. Biol. 25, 2853-2860.
10. Frescas, D. and Pagano, M. (2008). Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 8, 438-449.
11. Galaktionov, K., Lee, A. K., Eckstein, J., Draetta, G., Meckler, J., Loda, M. and Beach, D. (1995). CDC25 phosphatases as potential human oncogenes. Science 269, 1575-1577.
12. Guardavaccaro, D., Kudo, Y., Boulaire, J., Barchi, M., Busino, L., Donzelli, M., Margottin-Goguet, F., Jackson, P. K., Yamasaki, L. and Pagano, M. (2003). Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev. Cell 4, 799-812.
13. beta-TrCP-dependent degradation for cell cycle arrest. Mol. Biol. Cell 20, 2186-2195.
14. beta-TrCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev. 17, 3062-3074.
15. Kakizuka, A., Sebastian, B., Borgmeyer, U., Hermans-Borgmeyer, I., Bolado, J., Hunter, T., Hoekstra, M. F. and Evans, R. M. (1992). A mouse cdc25 homolog is differentially and developmentally expressed. Genes Dev. 6, 578-590.
16. Kanemori, Y., Uto, K. and Sagata, N. (2005). Beta-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc. Natl. Acad. Sci. USA 102, 6279-6284.
17. Karlsson, C., Katich, S., Hagting, A., Hoffmann, I. and Pines, J. (1999). Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. J. Cell Biol. 146, 573-584.
18. Kristjansdottir, K. and Rudolph, J. (2004). Cdc25 phosphatases and cancer. Chem. Biol. 11, 1043-1051.
19. Latres, E., Chiaur, D. S. and Pagano, M. (1999). The human F box protein beta-TrCP associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 18, 849-854.
20. Lee, G., White, L. S., Hurov, K. E., Stappenbeck, T. S. and Piwnica-Worms, H. (2009). Response of small intestinal epithelial cells to acute disruption of cell division through CDC25 deletion. Proc. Natl. Acad. Sci. USA 106, 4701-4706.
21. Lincoln, A. J., Wickramasinghe, D., Stein, P., Schultz, R. M., Palko, M. E., De Miguel, M. P., Tessarollo, L. and Donovan, P. J. (2002). Cdc25b phosphatase is required for resumption of meiosis during oocyte maturation. Nat. Genet. 30, 446-449.
22. Ma, Z. Q., Chua, S. S., DeMayo, F. J. and Tsai, S. Y. (1999). Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B. Oncogene 18, 4564-4576.
23. betaTrCP/Slimb ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev. Cell 4, 813-826.
24. Melixetian, M., Klein, D. K., Sorensen, C. S. and Helin, K. (2009). NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint. Nat. Cell Biol. 11, 1247-1253.
25. Miyata, H., Doki, Y., Yamamoto, H., Kishi, K., Takemoto, H., Fujiwara, Y., Yasuda, T., Yano, M., Inoue, M., Shiozaki, H. et al. (2001). Overexpression of CDC25B overrides radiation-induced G2-M arrest and results in increased apoptosis in esophageal cancer cells. Cancer Res. 61, 3188-3193.
26. Morgan, D. O. (1995). Principles of CDK regulation. Nature 374, 131-134.
27. Ray, D., Terao, Y., Nimbalkar, D., Hirai, H., Osmundson, E. C., Zou, X., Franks, R., Christov, K. and Kiyokawa, H. (2007). Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res. 67, 6605-6611.
28. Seki, A., Coppinger, J. A., Du, H., Jang, C. Y., Yates, J. R., 3rd and Fang, G. (2008). Plk1-and beta-TrCP-dependent degradation of Bora controls mitotic progression. J. Cell Biol. 181, 65-78.
29. Uchida, S., Kuma, A., Ohtsubo, M., Shimura, M., Hirata, M., Nakagama, H., Matsunaga, T., Ishizaka, Y. and Yamashita, K. (2004). Binding of 14-3-3beta but not 14-3-3sigma controls the cytoplasmic localization of CDC25B: binding site preferences of 14-3-3 subtypes and the subcellular localization of CDC25B. J. Cell Sci. 117, 3011-3020.
30. Uchida, S., Yoshioka, K., Kizu, R., Nakagama, H., Matsunaga, T., Ishizaka, Y., Poon, R. Y. and Yamashita, K. (2009). Stress-activated mitogen-activated protein kinases c-Jun NH2-terminal kinase and p38 target Cdc25B for degradation. Cancer Res. 69, 6438-6444.
31. beta-TrCP. Proc. Natl. Acad. Sci. USA 101, 4419-4424.
32. beta-TrCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 452, 370-374.
33. beta-TrCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro. Genes Dev. 13, 270-283.
34. beta-TrCP1 ubiquitin ligase. Mol. Cell 11, 1445-1456.
35. Yao, Y., Slosberg, E. D., Wang, L., Hibshoosh, H., Zhang, Y. J., Xing, W. Q., Santella, R. M. and Weinstein, I. B. (1999). Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice. Oncogene 18, 5159-5166.